MK-1439A (doravirine/tenofovir disoproxil fumarate/lamivudine)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-1439A (doravirine/tenofovir disoproxil fumarate/lamivudine), covering 2019-08-29 to 2019-08-29. Get the full timeline:
Most recent: Clinical Trial Update: Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) [Phase 2]